EUR/USD 1.1482 ▼ 0.03%GBP/USD 1.3386 ▼ 0.05%USD/JPY 156.7222 ▼ 0.10%USD/CHF 0.8230 ▲ 0.05%EUR/CHF 0.9446 ▼ 0.03%BTC/USD 81,490 ▲ 0.38%ETH/USD 2,659.44 ▲ 0.54%SOL/USD 111.2 ▲ 0.03%XAU/USD 4,378.25 ▼ 0.04%EUR/USD 1.1482 ▼ 0.03%GBP/USD 1.3386 ▼ 0.05%USD/JPY 156.7222 ▼ 0.10%USD/CHF 0.8230 ▲ 0.05%EUR/CHF 0.9446 ▼ 0.03%BTC/USD 81,490 ▲ 0.38%ETH/USD 2,659.44 ▲ 0.54%SOL/USD 111.2 ▲ 0.03%XAU/USD 4,378.25 ▼ 0.04%
Finance Review DailyMARKETS • BUSINESS • ECONOMY
EILMELDUNG
Graphic Packaging Raises Free Cash Flow Guidance, Eyes Mid-Teen Margins•Braze Raises Operating Margin Guidance Amid AI Acceleration•Dell CFO says AI server demand surges, lifts FY27 guidance by 70%•Crypto Markets Rally as US Clarity Act Fails; SEC, CFTC Move on Rules•Oil Prices Climb Further on Escalating Middle East Tensions•Graphic Packaging Raises Free Cash Flow Guidance, Eyes Mid-Teen Margins•Braze Raises Operating Margin Guidance Amid AI Acceleration•Dell CFO says AI server demand surges, lifts FY27 guidance by 70%•Crypto Markets Rally as US Clarity Act Fails; SEC, CFTC Move on Rules•Oil Prices Climb Further on Escalating Middle East Tensions•
ADVERTISEMENT
LIVE-DESK·Globale Marktredaktion·Last updated 14s ago
ADVERTISEMENT
Märkte/AktienArticle

Helus Pharma presents data on depression drug candidate HLP003

Finance Review Daily is tracking this developing story; further verified details were not immediately available.

PA
Priya Anand · Equities & Earnings Desk · 21 Sept 2026 · 12:22 · 1 Min. Lesezeit
Teilen
Helus Pharma presents data on depression drug candidate HLP003

Helus Pharma presents data on depression drug candidate HLP003.

Finance Review Daily is tracking this development following a report from Investing.com – Company News. Finance Review Daily will provide updates as verified details become available.

Dieser Artikel wurde mit KI-Unterstützung erstellt und von einer Finances-Review-Redakteurin bearbeitet.
ADVERTISEMENT
Artikel teilen
PA
Geschrieben von
Priya Anand
Equities & Earnings Desk

Priya covers listed equities and corporate earnings, reading quarterly results and guidance for what they signal about sector health and forward valuations.

Mehr von Priya Anand →
ADVERTISEMENT

Marktüberblick

Verzögert
EUR/USD1.1482▼ 0.03%GBP/USD1.3386▼ 0.05%USD/CHF0.8230▲ 0.05%BTC/USD81,490▲ 0.38%ETH/USD2,659.44▲ 0.54%XAU/USD4,378.25▼ 0.04%

Das könnte Sie auch interessieren

Lakewood-Amedex to launch Phase 2a trial of Nu-3 Gel for diabetic foot ulcers
Aktien

Lakewood-Amedex to launch Phase 2a trial of Nu-3 Gel for diabetic foot ulcers

Priya Anand · vor 10 Min.
ADVERTISEMENT